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High-Density Lipoprotein
Shortens the Ventricular
Action Potential
A Novel Explanation for How Statins
Prevent Sudden Arrhythmic Death?*
Paulus Kirchhof, MD, Larissa Fabritz, MD
Münster, Germany
Although therapy for acute coronary syndromes and chronic
coronary artery disease has improved markedly in past years
(1,2), resulting in a population-wide increase in life expec-
tancy due to better survival after myocardial infarction (3),
acute ischemia remains among the most common causes of
sudden arrhythmic death (4).
Preventing sudden arrhythmic death in patients at suffi-
ciently high risk to warrant the implantation of a defibril-
lator is simple (4). Patients whose risk for sudden death is
only slightly elevated (e.g., those with preserved left ven-
tricular function with or without known coronary artery
disease) require other, safer and less invasive interventions
for the primary prevention of sudden death (5). This clinical
dilemma is not new but remains largely unresolved (6).
See page 40
High low-density lipoprotein (LDL) cholesterol and low
high-density lipoprotein (HDL) cholesterol levels are asso-
ciated with myocardial infarction and death (7–9). Lower-
ing LDL cholesterol and increasing HDL cholesterol with
statin therapy prevents myocardial infarctions and other
manifestations of coronary artery disease and prolongs life
(10,11). Statins also appear to prevent sudden death in
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randomized trials (12,13), an effect that is also found in
meta-analyses (5). This “antiarrhythmic” effect of statins is
usually attributed to their ability to stabilize coronary
plaques and to prevent reinfarctions (14,15). Statin therapy,
which lowers LDL cholesterol and raises HDL cholesterol,
can also prevent recurrent ventricular arrhythmias requiring
defibrillator therapy (16). Furthermore, ventricular arrhyth-
mias in the setting of acute myocardial infarction have
become uncommon in coronary care units when patients are
managed by early revascularization and the immediate
initiation of statin therapy (1,17–19).
In this issue of the Journal, Den Ruijter et al. (20) report
a convincing, simple, and elegant study of the effects of
reconstituted HDL cholesterol on the QT interval and the
ventricular action potential. They clearly show that HDL
particles shorten the ventricular action potential in isolated
cardiomyocytes and the QT interval in healthy human
subjects. The study thereby reports a potentially important
and thus far underrecognized effect of HDL cholesterol on
the heart.
Why might shortening of the QT interval by reconsti-
tuted HDL be relevant? Prolonging the QT interval is a
feared side effect of many antiarrhythmic and noncardiac
drugs and can provoke ventricular torsades de pointes
arrhythmias (21). This drug-induced proarrhythmia is usu-
ally associated with inhibition of the rapid component of the
delayed inward rectifier and precipitated by spontaneous
depolarizations, which can be appreciated as giant T-U
waves on surface electrocardiography (22).
Acute ischemia initially prolongs the ventricular action
potential and the QT interval (23,24). Similarly, early
reperfusion also acutely and markedly prolongs the QT
interval (25). Comparable with the situation in inherited
and acquired long-QT syndrome, ventricular arrhythmias
are likely in this setting (Fig. 1). As acute regional ischemia
additionally provokes local inhomogeneities of repolariza-
tion by prolonging the QT interval in the ischemic zone
while maintaining normal action potentials in well-perfused
areas of the ventricles, a substrate for ventricular fibrillation
is generated. This is sufficient to maintain ventricular
arrhythmias, as shown, for example, in cardiomyocyte layers
subjected to acute ischemia (26). The presence of elevated
levels of HDL could prevent ischemia-induced prolonga-
tion of the action potential in the ischemic zone, reduce
differences in action potential duration during acute isch-
emia, and thereby prevent ventricular arrhythmias.
At present, this potential antiarrhythmic effect of HDL is
only a speculation in an editorial comment, and further
testing of such effects is clearly warranted. Open questions
include whether the QT-shortening effect of HDL is
maintained in ischemic myocardium; whether there is a
dose-response relationship of HDL levels and prolongation
of ventricular repolarization; of what magnitude would the
effect be in vivo, in which the shortening of the QT interval
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HDL and SCD June 28, 2011:45–7is less obvious than the shortening of the ventricular action
potential (compare Fig. 1A with Fig. 2B in Den Ruijter et
al. [20]); whether integration of HDL in the cell membrane
or in other cellular compartments is needed to mediate the
action potential shortening; and which ion currents are
altered to mediate shortening of the action potential upon
challenge with HDL. The study by Den Ruijter et al. invites
further investigations into the QT-shortening effect of
biological lipoproteins by convincingly demonstrating that
HDL, at least in its reconstituted form, shortens the
ventricular action potential in cardiomyocytes and the QT
interval in humans. It is a welcome first step toward
understanding the effects of HDL cholesterol on the vas-
cular and electrical function of the heart.
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